|Systematic (IUPAC) name|
|14px (what is this?)|
CB-13 (CRA13, SAB-378) is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies, and has progressed to preliminary human trials.
- Cluny, N. L.; Keenan, C. M.; Duncan, M.; Fox, A.; Lutz, B.; Sharkey, K. A. (2010). "Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice". Journal of Pharmacology and Experimental Therapeutics 334 (3): 973–80. PMID 20571060. doi:10.1124/jpet.110.169946.
- Gardin A, Kucher K, Kiese B, Appel-Dingemanse S (April 2009). "Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety". Drug Metabolism and Disposition: the Biological Fate of Chemicals 37 (4): 827–33. PMID 19144772. doi:10.1124/dmd.108.024000.
Lua error in package.lua at line 80: module 'Module:Buffer' not found.